BACKGROUND: Melanoma has the highest rate of spread to the leptomeninges and the incidence of melanoma has been steadily rising. This article describes recent experience at the Lille University Hospital, between 2007 and 2011 and discusses the possibilities for treatment of leptomeningeal metastasis. PATIENTS AND METHODS: Nine patients were diagnosed with leptomeningeal metastasis of melanoma. The standard criteria were used for the diagnosis. The treatment consisted of a combination of intrathecal chemotherapy, systemic chemotherapy and best supportive care. RESULTS: The overall median survival from the time of leptomeningeal metastasis diagnosis was eight weeks (range=1-168 weeks). In two cases, the median overall survival was 104 weeks. For these patients, there was a clear benefit in intrathecal chemotherapy combined with systemic treatment. No complication was observed. CONCLUSION: Despite a poor prognosis, treatment of melanoma leptomeningeal metastasis is needed in order to improve the quality of life, neurological progression-free survival and overall survival of patients.
BACKGROUND:Melanoma has the highest rate of spread to the leptomeninges and the incidence of melanoma has been steadily rising. This article describes recent experience at the Lille University Hospital, between 2007 and 2011 and discusses the possibilities for treatment of leptomeningeal metastasis. PATIENTS AND METHODS: Nine patients were diagnosed with leptomeningeal metastasis of melanoma. The standard criteria were used for the diagnosis. The treatment consisted of a combination of intrathecal chemotherapy, systemic chemotherapy and best supportive care. RESULTS: The overall median survival from the time of leptomeningeal metastasis diagnosis was eight weeks (range=1-168 weeks). In two cases, the median overall survival was 104 weeks. For these patients, there was a clear benefit in intrathecal chemotherapy combined with systemic treatment. No complication was observed. CONCLUSION: Despite a poor prognosis, treatment of melanoma leptomeningeal metastasis is needed in order to improve the quality of life, neurological progression-free survival and overall survival of patients.
Authors: Inna Smalley; Vincent Law; Clayton Wyatt; Brittany Evernden; Bin Fang; John M Koomen; Eric A Welsh; Robert J B Macaulay; Peter A Forsyth; Keiran S M Smalley Journal: Clin Cancer Res Date: 2020-01-10 Impact factor: 12.531
Authors: Keiran S M Smalley; Inna V Fedorenko; Rajappa S Kenchappa; Solmaz Sahebjam; Peter A Forsyth Journal: Int J Cancer Date: 2016-04-30 Impact factor: 7.396
Authors: Isabella C Glitza; Cara Haymaker; Chantale Bernatchez; Luis Vence; Michelle Rohlfs; Jessie Richard; Carol Lacey; Rahmatu Mansaray; Orenthial J Fulbright; Renjith Ramachandran; Christopher Toth; Seth Wardell; Sapna P Patel; Scott E Woodman; Wen-Jen Hwu; Laszlo G Radvanyi; Michael A Davies; Nicholas E Papadopoulos; Patrick Hwu Journal: Cancer Immunol Res Date: 2015-07-27 Impact factor: 11.151
Authors: Justine V Cohen; Hussain Tawbi; Kim A Margolin; Ravi Amravadi; Marcus Bosenberg; Priscilla K Brastianos; Veronica L Chiang; John de Groot; Isabella C Glitza; Meenhard Herlyn; Sheri L Holmen; Lucia B Jilaveanu; Andrew Lassman; Stergios Moschos; Michael A Postow; Reena Thomas; John A Tsiouris; Patrick Wen; Richard M White; Timothy Turnham; Michael A Davies; Harriet M Kluger Journal: Pigment Cell Melanoma Res Date: 2016-10-22 Impact factor: 4.693
Authors: Dae Won Kim; Edelyn Barcena; Urvi N Mehta; Michelle L Rohlfs; Ashok J Kumar; Marta Penas-Prado; Kevin B Kim Journal: BMC Cancer Date: 2015-05-13 Impact factor: 4.430